TY - JOUR
T1 - Erythropoietin levels in heart failure after an acute myocardial infarction
T2 - Determinants, prognostic value, and the effects of captopril versus losartan
AU - Belonje, Anne M S
AU - Westenbrink, B. Daan
AU - Voors, Adriaan A.
AU - Haehling, Stephan von
AU - Ponikowski, Pjotr
AU - Anker, Stefan D.
AU - van Veldhuisen, Dirk J.
AU - Dickstein, Kenneth
PY - 2009/1
Y1 - 2009/1
N2 - Background: In patients with chronic heart failure, erythropoietin (Epo) levels are increased and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak correlation with hemoglobin levels. Methods: This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure. We investigated the determinants and the prognostic role of elevated Epo levels in these patients, and we studied the change in Epo levels by either captopril or losartan. Results: The correlation between Epo and hemoglobin at baseline (r = 0.348, P <.001) and after 1 month (r = 0.272, P
AB - Background: In patients with chronic heart failure, erythropoietin (Epo) levels are increased and related to a poor prognosis. Furthermore, Epo levels in these patients show a weak correlation with hemoglobin levels. Methods: This is a retrospective analysis of a subgroup of the OPTIMAAL (Optimal Trial in Myocardial Infarction with the Angiotensin II Antagonist Losartan) trial in which serum Epo levels were measured at baseline, at 1 month, and at 1 and 2 years in 224 patients with an acute myocardial infarction complicated by signs or symptoms of heart failure. We investigated the determinants and the prognostic role of elevated Epo levels in these patients, and we studied the change in Epo levels by either captopril or losartan. Results: The correlation between Epo and hemoglobin at baseline (r = 0.348, P <.001) and after 1 month (r = 0.272, P
UR - http://www.scopus.com/inward/record.url?scp=57149093397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=57149093397&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2008.08.020
DO - 10.1016/j.ahj.2008.08.020
M3 - Article
C2 - 19081402
AN - SCOPUS:57149093397
SN - 0002-8703
VL - 157
SP - 91
EP - 96
JO - American Heart Journal
JF - American Heart Journal
IS - 1
ER -